Compare ARCC & DVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ARCC | DVA |
|---|---|---|
| Founded | 2004 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Misc Health and Biotechnology Services |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.6B | 13.5B |
| IPO Year | 2004 | 2003 |
| Metric | ARCC | DVA |
|---|---|---|
| Price | $18.06 | $209.42 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 11 | 4 |
| Target Price | $21.36 | ★ $156.75 |
| AVG Volume (30 Days) | ★ 4.8M | 594.4K |
| Earning Date | 04-28-2026 | 05-05-2026 |
| Dividend Yield | ★ 10.28% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | 0.13 | ★ 2.87 |
| Revenue | N/A | ★ $13,643,069,000.00 |
| Revenue This Year | $5.77 | $3.85 |
| Revenue Next Year | $2.29 | $3.07 |
| P/E Ratio | $138.69 | ★ $72.41 |
| Revenue Growth | N/A | ★ 6.46 |
| 52 Week Low | $17.40 | $101.00 |
| 52 Week High | $23.42 | $213.44 |
| Indicator | ARCC | DVA |
|---|---|---|
| Relative Strength Index (RSI) | 34.23 | 68.51 |
| Support Level | $17.49 | $189.09 |
| Resistance Level | $19.38 | N/A |
| Average True Range (ATR) | 0.29 | 5.84 |
| MACD | -0.10 | 0.38 |
| Stochastic Oscillator | 0.39 | 82.56 |
Ares Capital Corp is a United States-based closed-ended specialty finance company. Its investment objective is to generate both current income and capital appreciation through debt and equity investments. The company focuses on investing in first lien senior secured loans (including unitranche loans, which are loans that combine both senior and subordinated debt, generally in a first lien position) and second lien senior secured loans. In addition to senior secured loans, the company also invests in subordinated loans and preferred equity, it also makes common equity investments.
DaVita is one of the largest providers of dialysis services in the United States, boasting a market share of about 35%. The firm operates over 3,200 facilities worldwide, mostly in the US, and treats about 300,000 patients annually. Government payers dominate US dialysis reimbursement. DaVita receives about two-thirds of US sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. While commercial insurers represent only about 10% of US patients treated, they represent nearly all of the profits generated by DaVita in the US dialysis business.